MedTrace Logo

Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells

NCT03865394 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2021-10-14

No results posted yet for this study

Summary

The aim of this study is to investigate efficiency of applying of adipose-derived mesenchymal stem cells (ADSC) in treatment of chronic wounds in diabetic foot syndrome.

Conditions

  • Diabetic Foot Ulcer

Interventions

BIOLOGICAL

Application of allogeneic ADSC stem cells in fibrin gel

Chronic wounds in diabetic foot ulcer will be covered with ADSC suspended in fibrin gel - single dose will be administered followed by weekly wound control.

PROCEDURE

Standard care in diabetic foot ulcer

Chronic wounds in diabetic foot ulcer will be covered with fibrin gel followed by weekly wound control.

Sponsors & Collaborators

  • Polish Stem Cells Bank S.A.

    collaborator UNKNOWN

  • Medical University of Warsaw

    lead OTHER

Principal Investigators

  • Beata Mrozikiewicz-Rakowska, . Assoc.Prof. · Medical University of Warsaw, Department of Diabetology and Internal Diseases

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2021-03-31
Completion
2021-09-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03865394 on ClinicalTrials.gov